FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2106203516> ?p ?o ?g. }

• W2106203516 endingPage "1481.e3" @default.
• W2106203516 startingPage "1473" @default.
• W2106203516 abstract "Background & AimsTeduglutide, a glucagon-like peptide 2 analogue, might restore intestinal structural and functional integrity by promoting growth of the mucosa and reducing gastric emptying and secretion. These factors could increase fluid and nutrient absorption in patients with short bowel syndrome with intestinal failure (SBS-IF). We performed a prospective study to determine whether teduglutide reduces parenteral support in patients with SBS-IF.MethodsWe performed a 24-week study of patients with SBS-IF who were given subcutaneous teduglutide (0.05 mg/kg/d; n = 43) or placebo (n = 43) once daily. Parenteral support was reduced if 48-hour urine volumes exceeded baseline values by ≥10%. The primary efficacy end point was number of responders (patients with >20% reduction in parenteral support volume from baseline at weeks 20 and 24).ResultsThere were significantly more responders in the teduglutide group (27/43 [63%]) than the placebo group (13/43 [30%]; P = .002). At week 24, the mean reduction in parenteral support volume in the teduglutide group was 4.4 ± 3.8 L/wk (baseline 12.9 ± 7.8 L/wk) compared with 2.3 ± 2.7 L/wk (baseline 13.2 ± 7.4 L/wk) in the placebo group (P < .001). The percentage of patients with a 1-day or more reduction in the weekly need for parenteral support was greater in the teduglutide group (21/39 [54%]) than in the placebo group (9/39 [23%]; P = .005). Teduglutide increased plasma concentrations of citrulline, a biomarker of mucosal mass. The distribution of treatment-emergent adverse events that led to study discontinuation was similar between patients given teduglutide (n = 2) and placebo (n = 3).ConclusionsTwenty-four weeks of teduglutide treatment was generally well tolerated in patients with SBS-IF. Treatment with teduglutide reduced volumes and numbers of days of parenteral support for patients with SBS-IF; ClinicalTrials.gov Number, NCT00798967. Teduglutide, a glucagon-like peptide 2 analogue, might restore intestinal structural and functional integrity by promoting growth of the mucosa and reducing gastric emptying and secretion. These factors could increase fluid and nutrient absorption in patients with short bowel syndrome with intestinal failure (SBS-IF). We performed a prospective study to determine whether teduglutide reduces parenteral support in patients with SBS-IF. We performed a 24-week study of patients with SBS-IF who were given subcutaneous teduglutide (0.05 mg/kg/d; n = 43) or placebo (n = 43) once daily. Parenteral support was reduced if 48-hour urine volumes exceeded baseline values by ≥10%. The primary efficacy end point was number of responders (patients with >20% reduction in parenteral support volume from baseline at weeks 20 and 24). There were significantly more responders in the teduglutide group (27/43 [63%]) than the placebo group (13/43 [30%]; P = .002). At week 24, the mean reduction in parenteral support volume in the teduglutide group was 4.4 ± 3.8 L/wk (baseline 12.9 ± 7.8 L/wk) compared with 2.3 ± 2.7 L/wk (baseline 13.2 ± 7.4 L/wk) in the placebo group (P < .001). The percentage of patients with a 1-day or more reduction in the weekly need for parenteral support was greater in the teduglutide group (21/39 [54%]) than in the placebo group (9/39 [23%]; P = .005). Teduglutide increased plasma concentrations of citrulline, a biomarker of mucosal mass. The distribution of treatment-emergent adverse events that led to study discontinuation was similar between patients given teduglutide (n = 2) and placebo (n = 3). Twenty-four weeks of teduglutide treatment was generally well tolerated in patients with SBS-IF. Treatment with teduglutide reduced volumes and numbers of days of parenteral support for patients with SBS-IF; ClinicalTrials.gov Number, NCT00798967." @default.
• W2106203516 created "2016-06-24" @default.
• W2106203516 creator A5019112797 @default.
• W2106203516 creator A5020148523 @default.
• W2106203516 creator A5038221938 @default.
• W2106203516 creator A5042678984 @default.
• W2106203516 creator A5043694977 @default.
• W2106203516 creator A5069756420 @default.
• W2106203516 creator A5074424756 @default.
• W2106203516 creator A5080166750 @default.
• W2106203516 creator A5091324781 @default.
• W2106203516 date "2012-12-01" @default.
• W2106203516 modified "2023-10-14" @default.
• W2106203516 title "Teduglutide Reduces Need for Parenteral Support Among Patients With Short Bowel Syndrome With Intestinal Failure" @default.
• W2106203516 cites W1528053188 @default.
• W2106203516 cites W1978770979 @default.
• W2106203516 cites W2004694925 @default.
• W2106203516 cites W2017662439 @default.
• W2106203516 cites W2060942956 @default.
• W2106203516 cites W2072107304 @default.
• W2106203516 cites W2083616160 @default.
• W2106203516 cites W2085752806 @default.
• W2106203516 cites W2090245368 @default.
• W2106203516 cites W2098309233 @default.
• W2106203516 cites W2109745718 @default.
• W2106203516 cites W2127068727 @default.
• W2106203516 cites W2138411980 @default.
• W2106203516 cites W2148592311 @default.
• W2106203516 cites W2158564298 @default.
• W2106203516 cites W2159328216 @default.
• W2106203516 cites W2163922678 @default.
• W2106203516 cites W2178262235 @default.
• W2106203516 doi "https://doi.org/10.1053/j.gastro.2012.09.007" @default.
• W2106203516 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22982184" @default.
• W2106203516 hasPublicationYear "2012" @default.
• W2106203516 type Work @default.
• W2106203516 sameAs 2106203516 @default.
• W2106203516 citedByCount "353" @default.
• W2106203516 countsByYear W21062035162012 @default.
• W2106203516 countsByYear W21062035162013 @default.
• W2106203516 countsByYear W21062035162014 @default.
• W2106203516 countsByYear W21062035162015 @default.
• W2106203516 countsByYear W21062035162016 @default.
• W2106203516 countsByYear W21062035162017 @default.
• W2106203516 countsByYear W21062035162018 @default.
• W2106203516 countsByYear W21062035162019 @default.
• W2106203516 countsByYear W21062035162020 @default.
• W2106203516 countsByYear W21062035162021 @default.
• W2106203516 countsByYear W21062035162022 @default.
• W2106203516 countsByYear W21062035162023 @default.
• W2106203516 crossrefType "journal-article" @default.
• W2106203516 hasAuthorship W2106203516A5019112797 @default.
• W2106203516 hasAuthorship W2106203516A5020148523 @default.
• W2106203516 hasAuthorship W2106203516A5038221938 @default.
• W2106203516 hasAuthorship W2106203516A5042678984 @default.
• W2106203516 hasAuthorship W2106203516A5043694977 @default.
• W2106203516 hasAuthorship W2106203516A5069756420 @default.
• W2106203516 hasAuthorship W2106203516A5074424756 @default.
• W2106203516 hasAuthorship W2106203516A5080166750 @default.
• W2106203516 hasAuthorship W2106203516A5091324781 @default.
• W2106203516 hasConcept C126322002 @default.
• W2106203516 hasConcept C142724271 @default.
• W2106203516 hasConcept C168563851 @default.
• W2106203516 hasConcept C185592680 @default.
• W2106203516 hasConcept C197934379 @default.
• W2106203516 hasConcept C202061045 @default.
• W2106203516 hasConcept C203092338 @default.
• W2106203516 hasConcept C204787440 @default.
• W2106203516 hasConcept C27081682 @default.
• W2106203516 hasConcept C2779281246 @default.
• W2106203516 hasConcept C2779820108 @default.
• W2106203516 hasConcept C2781219945 @default.
• W2106203516 hasConcept C2991744798 @default.
• W2106203516 hasConcept C55493867 @default.
• W2106203516 hasConcept C71924100 @default.
• W2106203516 hasConcept C78722104 @default.
• W2106203516 hasConcept C90924648 @default.
• W2106203516 hasConceptScore W2106203516C126322002 @default.
• W2106203516 hasConceptScore W2106203516C142724271 @default.
• W2106203516 hasConceptScore W2106203516C168563851 @default.
• W2106203516 hasConceptScore W2106203516C185592680 @default.
• W2106203516 hasConceptScore W2106203516C197934379 @default.
• W2106203516 hasConceptScore W2106203516C202061045 @default.
• W2106203516 hasConceptScore W2106203516C203092338 @default.
• W2106203516 hasConceptScore W2106203516C204787440 @default.
• W2106203516 hasConceptScore W2106203516C27081682 @default.
• W2106203516 hasConceptScore W2106203516C2779281246 @default.
• W2106203516 hasConceptScore W2106203516C2779820108 @default.
• W2106203516 hasConceptScore W2106203516C2781219945 @default.
• W2106203516 hasConceptScore W2106203516C2991744798 @default.
• W2106203516 hasConceptScore W2106203516C55493867 @default.
• W2106203516 hasConceptScore W2106203516C71924100 @default.
• W2106203516 hasConceptScore W2106203516C78722104 @default.
• W2106203516 hasConceptScore W2106203516C90924648 @default.
• W2106203516 hasFunder F4320332542 @default.
• W2106203516 hasIssue "6" @default.
• W2106203516 hasLocation W21062035161 @default.
• W2106203516 hasLocation W21062035162 @default.

• next